PF-Atlas › Treatments › Lung-on-Chip + AI Drug Screening
Lung-on-Chip + AI Drug Screening
Emulate Bio platform screens drug combinations in hours vs months
PF-Atlas model — Computational / preclinical hypothesis — not clinically validated. How PF-Atlas grades evidence.
Development stage
Available Now
Evidence level
Level 4 (Platform)
Mechanism class
Emulate Bio platform screens drug combinations in hours vs months
Timeline
1 year
Risk profile
Low
Developer
Wyss Institute / Emulate
Key researchers
D. Ingber
Overview
IPF lung-on-chip recapitulates AEC2 dysfunction + fibroblast activation. Run 1000 combinations in parallel.
How Lung-on-Chip + AI Drug Screening fits into IPF treatment
Lung-on-Chip + AI Drug Screening is classified as Level 4 (Platform) at the Available Now stage. Explore how it compares to other options and where it sits in the development pipeline:
Other IPF treatments
Medical disclaimer. This page summarizes published research and PF-Atlas model output about Lung-on-Chip + AI Drug Screening for information only. It is not medical advice or a treatment recommendation. Drug availability, approval status and evidence change — verify with a pulmonologist and official sources (FDA, ClinicalTrials.gov) before any decision.